Cancer stem cells: Targets and potential biomarkers for radiotherapy

Clinical Cancer Research

Volumn 17, Issue 23, 2011, Pages 7224-7229

  Krause, Mechthild ^a   Yaromina, Ala ^a   Eicheler, Wolfgang ^a   Koch, Ulrike ^a   Baumann, Michael ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELL SURFACE MARKER; REACTIVE OXYGEN METABOLITE;

CANCER CONTROL; CANCER INHIBITION; CANCER PATIENT; CANCER RESISTANCE; CANCER RISK; CANCER STEM CELL; CANCER THERAPY; CELL COUNT; CELL POPULATION; CELL SPECIFICITY; CLINICAL STUDY; DRUG SCREENING; HISTOLOGY; HUMAN; MULTIMODALITY CANCER THERAPY; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOTHERAPY; REOXYGENATION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR RECURRENCE; TUMOR VOLUME;

COMBINED MODALITY THERAPY; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; NEOPLASTIC STEM CELLS; RADIATION TOLERANCE; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 82555205497     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2639     Document Type: Review

References (61)

1. Baumann M, Herrmann T, Koch R, Matthiessen W, Appold S, Wahlers B, et al. Final results of the randomized phase IIICHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol 2011;100:76-85.
2. Budach V, Stuschke M, Budach W, Baumann M, Geismar D, Grabenbauer G, et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 2005;23:1125-35. (Pubitemid 46202268)
3. Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997;15:2040-9. (Pubitemid 27209535)
4. Guckenberger M, Wulf J, Mueller G, Krieger T, Baier K, Gabor M, et al. Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. Int J Radiat Oncol Biol Phys 2009;74:47-54.
5. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008;8:545-54. (Pubitemid 351881850)
6. Hill RP, Milas L. The proportion of stem cells in murine tumors. Int J Radiat Oncol Biol Phys 1989;16:513-8. (Pubitemid 19077222)
7. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells - perspectives on current status and future directions: AACR Workshop on Cancer Stem Cells. Cancer Res 2006;66:9339-44.
8. Krause M, Zips D, Thames HD, Kummermehr J, Baumann M. Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. Radiother Oncol 2006;80:112-22. (Pubitemid 44314014)
9. Baumann M, Krause M, Thames H, Trott K, Zips D. Cancer stem cells and radiotherapy. Int J Radiat Biol 2009;85:391-402.
10. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006;444:756-60. (Pubitemid 44949604)
11. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009;458:780-3.
12. Baumann M, Dubois W, Suit HD. Response of human squamous cell carcinoma xenografts of different sizes to irradiation: relationship of clonogenic cells, cellular radiation sensitivity in vivo, and tumor rescuing units. Radiat Res 1990;123:325-30. (Pubitemid 20327905)
13. Dubben HH, Thames HD, Beck-Bornholdt HP. Tumor volume: a basic and specific response predictor in radiotherapy. [see comments] Radiother Oncol 1998;47:167-74. (Pubitemid 28275927)
14. Gerweck LE, Zaidi ST, Zietman A. Multivariate determinants of radiocurability. I: Prediction of single fraction tumor control doses. Int J Radiat Oncol Biol Phys 1994;29:57-66. (Pubitemid 24138865)
15. Yaromina A, Krause M, Thames H, Rosner A, Krause M, Hessel F, et al. Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. Radiother Oncol 2007;83:304-10. (Pubitemid 46915546)
16. Baumann M, Krause M, Hill R. Clonogens and cancer stem cells. Nat Rev Cancer 2008;8:990.
17. Du L, Wang H, He L, Zhang J, Ni B, Wang X, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 2008;14:6751-60.
18. de Jong MC, Pramana J, van der Wal JE, Lacko M, Peutz-Kootstra CJ, de Jong JM, et al. CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin Cancer Res 2010;16:5329-38.
19. Warenius HM, Britten RA. In vitro studies of intrinsic cellular radiosensitivity following 4 MeV photons or 62.5 MeV (p->Be+) neutrons. Potential implications for high LET therapy. Acta Oncol 1994;33:241-9. (Pubitemid 24210787)
20. Malaise EP, Fertil B, Chavaudra N, Guichard M. Distribution of radiation sensitivities for human tumor cells of specific histological types: comparison of in vitro to in vivo data. Int J Radiat Oncol Biol Phys 1986;12:617-24. (Pubitemid 16081624)
21. Peters LJ. The ESTRO Regaud Lecture. Inherent radiosensitivity of tumor and normal tissue cells as a predictor of human tumor response. Radiother Oncol 1990;17:177-90. (Pubitemid 20110265)
22. Milas L, Yamada S, Hunter N, Guttenberger R, Thames HD. Changes in TCD50 as a measure of clonogen doubling time in irradiated and unirradiated tumors. Int J Radiat Oncol Biol Phys 1991;21:1195-202.
23. Baumann M, Dörr W, Petersen C, Krause M. Repopulation during fractionated radiotherapy: much has been learned, even more is open. Int J Radiat Biol 2003;79:465-7. (Pubitemid 37311050)
24. Petersen C, Zips D, Krause M, Schöne K, Eicheler W, Hoinkis C, et al. Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation. Int J Radiat Oncol Biol Phys 2001;51:483-93. (Pubitemid 32884296)
25. Hessel F, Krause M, Helm A, Petersen C, Grenman R, Thames HD, et al. Differentiation status of human squamous cell carcinoma xenografts does not appear to correlate with the repopulation capacity of clonogenic tumour cells during fractionated irradiation. Int J Radiat Biol 2004;80:719-27. (Pubitemid 40126088)
26. Hessel F, Krause M, Petersen C, Hörcsöki M, Klinger T, Zips D, et al. Repopulation of moderately well-differentiated and keratinizing GL human squamous cell carcinomas growing in nude mice. Int J Radiat Oncol Biol Phys 2004;58:510-8. (Pubitemid 38142478)
27. Vlashi E, Kim K, Lagadec C, Donna LD, McDonald JT, Eghbali M, et al. In vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst 2009;101:350-9.
28. Yaromina A, Zips D, Thames HD, Eicheler W, Krause M, Rosner A, et al. Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: the need for a multivariate approach in biomarker studies. Radiother Oncol 2006;81:122-9. (Pubitemid 44780780)
29. Yaromina A, Thames H, Zhou X, Hering S, Eicheler W, Dörfler A, et al. Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation. Radiother Oncol 2010;96:116-22.
30. Yaromina A, Quennet V, Zips D, Meyer S, Shakirin G, Walenta S, et al. Co-localisation of hypoxia and perfusion markers with parameters of glucose metabolism in human squamous cell carcinoma (hSCC) xenografts. Int J Radiat Biol 2009;85:972-80.
31. Quennet V, Yaromina A, Zips D, Rosner A, Walenta S, Baumann M, et al. Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol 2006;81:130-5. (Pubitemid 44780779)
32. Sattler UG, Meyer SS, Quennet V, Hoerner C, Knoerzer H, Fabian C, et al. Glycolytic metabolism and tumour response to fractionated irradiation. Radiother Oncol 2010;94:102-9.
33. Blazek ER, Foutch JL, Maki G. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 2007;67:1-5. (Pubitemid 44959518)
34. Platet N, Liu SY, Atifi ME, Oliver L, Vallette FM, Berger F, et al. Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett 2007;258:286-90. (Pubitemid 350110377)
35. Ezashi T, Das P, Roberts RM. Low O2 tensions and the prevention of differentiation of hES cells. Proc Natl Acad Sci US A 2005;102:4783-8. (Pubitemid 40471531)
36. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009;15:501-13.
37. Heddleston JM, Li Z, McLendon RE, Hjelmeland AB, Rich JN. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009;8:3274-84.
38. Baumann M, Krause M. CD44: a cancer stem cell-related biomarker with predictive potential for radiotherapy. Clin Cancer Res 2010;16:5091-3.
39. Ponta H, Sleeman J, Dall P, Moll J, Sherman L, Herrlich P. CD44 isoforms in metastatic cancer. Invasion Metastasis 1994-1995;14:82-6.
40. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003;4:33-45. (Pubitemid 36077255)
41. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J, et al. CD44 splice isoformswitching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 2011;121:1064-74.
42. Afify A, Pang L, Howell L. Diagnostic utility of CD44 standard, CD44v6, and CD44v3-10 expression in adenocarcinomas presenting in serous fluids. Appl Immunohistochem Mol Morphol 2007;15:446-50. (Pubitemid 350307852)
43. Gurtner K, Hessel F, Eicheler W, Dörfler A, Zips D, Heider KH, et al. Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumor control in vivo. Radiother Oncol. In Press.
44. Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011;8:97-106.
45. Shigdar S, Lin J, Yu Y, Pastuovic M, Wei M, Duan W. RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci 2011;102:991-8.
46. Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009;5:168-77.
47. Merchant AA, Matsui W. Targeting Hedgehog - a cancer stem cell pathway. Clin Cancer Res 2010;16:3130-40.
48. Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 2010;16:3153-62.
49. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B, et al. Targeting Notch to target cancer stem cells. Clin Cancer Res 2010;16:3141-52.
50. Stewart FA, Dörr W. Milestones in normal tissue radiation biology over the past 50 years: from clonogenic cell survival to cytokine networks and back to stem cell recovery. Int J Radiat Biol 2009;85:574-86.
51. Dörr W. Three A's of repopulation during fractionated irradiation of squamous epithelia: asymmetry loss, acceleration of stem-cell divisions and abortive divisions. Int J Radiat Biol 1997;72:635-43. (Pubitemid 28020327)
52. LaBarge MA. The difficulty of targeting cancer stem cell niches. Clin Cancer Res 2010;16:3121-9.
53. Gilbertson RJ, Rich JN. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 2007;7:733-6. (Pubitemid 47463683)
54. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007;129:465-72. (Pubitemid 46660978)
55. Kallman RF, Dorie MJ. Tumor oxygenation and reoxygenation during radiation therapy: their importance in predicting tumor response. Int J Radiat Oncol Biol Phys 1986;12:681-5. (Pubitemid 16081633)
56. Overgaard J, Eriksen JG, Nordsmark M, Alsner J, Horsman MR Danish Head and Neck Cancer Study Group. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 2005;6:757-64. (Pubitemid 41430716)
57. Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998;46:135-46. (Pubitemid 28109172)
58. Mörchel P, Melkus G, Yaromina A, Zips D, Baumann M, Jakob PM, et al. Correlating quantitative MR measurements of standardized tumor lines with histological parameters and tumor control dose. Radiother Oncol 2010;96:123-30.
59. Thorwarth D, Alber M. Implementation of hypoxia imaging into treatment planning and delivery. Radiother Oncol 2010;97:172-5.
60. Kaanders JH, Pop LA, Marres HA, Bruaset I, van den Hoogen FJ, Merkx MA, et al. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;52:769-78. (Pubitemid 34158740)
61. Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 2005;6:112-7. (Pubitemid 40197705)